Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers
June 24, 2020 01:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 36/2020 ...
Publication of manuscript on preclinical Proof-of-Concept of arimoclomol in Gaucher disease
November 27, 2018 08:51 ET
|
ORPHAZYME A/S
Orphazyme A/SInvestor news No....
Enrollment of first patient in Phase II clinical trial for Gaucher disease
June 21, 2018 03:17 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Poster presentation at WORLDSymposium™ 2018 – arimoclomol as clinical candidate for treatment of Gaucher disease
February 06, 2018 11:38 ET
|
ORPHAZYME A/S
Investor newsOrphazyme A/SNo. 02/2018 ...
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
March 09, 2017 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
December 14, 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today that the Company received a letter from Fundação Oswaldo...